A Phase 3 interventional study of Nirsevimab in Respiratory Syncytial Virus Infections, sponsored by AstraZeneca. Completed at 9 sites in Japan. Open to participants aged 0 Years to 1 Year. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 3, and was the 14th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 0 Years to 1 Year · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2003; this study’s year is marked. 1 started in 2023.
This study's enrollment of 33 is below the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 239 across the 12 interventional studies, 233 across the 2 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months.
Study details include
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Japanese infants of ≤12 months of age eligible to receive palivizumab in accordance with national or local guidelines and those who must meet at least one of the following conditions at the time of informed consent.
Exclusion Criteria:
Any serious concurrent medical condition (except those resulting in an immune deficiency condition), including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-RSV monoclonal antibody
Drug: Nirsevimab
Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
Also known as: MEDI8897
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs), and New-onset Chronic Diseases (NOCDs)
An AE was development of any untoward medical occurrence in a participant or clinical study participant administered medicinal product and which did not necessarily have causal relationship with this treatment. TEAEs were AEs whose onset occurred after receiving nirsevimab through 360 days post second dose. An SAE was any AE that resulted in death, was immediately life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly or birth defect or was an important medical event that might jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AESIs were based on assessment by investigators following the administration of nirsevimab. An NOCD was a newly diagnosed medical condition of chronic, ongoing nature post administration of study drug.
Time frame: From the first dose administration (Day 1) through 360 days post 2nd dose, study Day 511
Serum Concentrations of Nirsevimab
Serum samples were collected at specified timepoints to evaluate concentrations of nirsevimab at selected time points.
Time frame: Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose
Number of Participants With Anti-drug Antibody (ADA) Response to Nirsevimab
Blood samples were analyzed for the presence of ADAs for nirsevimab using an appropriately validated bioanalytical method.
Time frame: Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose
Serum Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibody (nAb) Levels
Blood samples were collected for the determination anti-RSV nAb in serum using an appropriately validated bioanalytical method.
Time frame: Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose
This Phase III, single-arm, open-label study was conducted at 9 investigational sites in Japan in infants (\< or equal to 12 months of age at enrolment) with congenital heart disease, chronic lung disease, immunocompromise, down syndrome, or born pre-term.
| Milestone | Nirsevimab 50 mg/100 mg |
|---|---|
| Started | 33 |
| Received study dose 1 | 33 |
| Received study dose 2 | 32 |
| Completed | 33 |
| Not completed | 0 |
Serum samples were collected at specified timepoints to evaluate concentrations of nirsevimab at selected time points.
| microgram/milliliter (mcg/mL) | Nirsevimab 50 mg/100 mg |
|---|---|
| Pre-dose Day 1 | 0 ± 0 |
| Pre-dose Day 151 | 24.362 ± 24.639 |
| Day 181 | 129.554 ± 19.090 |
| Day 301 | 36.239 ± 48.154 |
| Day 511 | 3.234 ± 111.784 |
Blood samples were analyzed for the presence of ADAs for nirsevimab using an appropriately validated bioanalytical method.
| Participants | Nirsevimab 50 mg/100 mg |
|---|---|
| Pre-dose Day 1 | 0 |
| Pre-dose Day 151 | 0 |
| Day 181 | 0 |
| Day 301 | 0 |
| Day 511 | 4 |
Blood samples were collected for the determination anti-RSV nAb in serum using an appropriately validated bioanalytical method.
| international units/mL | Nirsevimab 50 mg/100 mg |
|---|---|
| Pre-dose Day 1 | 254.6 ± 79.2 |
| Pre-dose Day 151 | 8127.4 ± 18.8 |
| Day 181 | 28552.2 ± 9.5 |
| Day 301 | 11241.0 ± 24.8 |
| Day 511 | 1302.1 ± 58.1 |
An AE was development of any untoward medical occurrence in a participant or clinical study participant administered medicinal product and which did not necessarily have causal relationship with this treatment. TEAEs were AEs whose onset occurred after receiving nirsevimab through 360 days post second dose. An SAE was any AE that resulted in death, was immediately life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly or birth defect or was an important medical event that might jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AESIs were based on assessment by investigators following the administration of nirsevimab. An NOCD was a newly diagnosed medical condition of chronic, ongoing nature post administration of study drug.
| Participants | Nirsevimab 50 mg/100 mg |
|---|---|
| TEAE | 32 |
| TESAE | 8 |
| AESI | 0 |
| NOCD | 1 |
Collected over From 1st dose through 360 days after 2nd dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nirsevimab | 0/32 (0%) | 8/32 (25%) | 32/32 (100%) |
| Event | Nirsevimab |
|---|---|
| Infantile spasmsNervous system disorders | 1/32 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 1/32 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/32 |
| BronchitisInfections and infestations | 1/32 |
| Bronchitis viralInfections and infestations | 1/32 |
| Metapneumovirus pneumoniaInfections and infestations | 1/32 |
| Pneumonia bacterialInfections and infestations | 1/32 |
| Viral sepsisInfections and infestations | 1/32 |
| Thermal burnInjury, poisoning and procedural complications | 1/32 |
| Gastroenteritis adenovirusInfections and infestations | 1/32 |
| Event | Nirsevimab |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 25/32 |
| PyrexiaGeneral disorders | 14/32 |
| Hand-foot-and-mouth diseaseInfections and infestations | 12/32 |
| Viral upper respiratory tract infectionInfections and infestations | 10/32 |
| DiarrhoeaGastrointestinal disorders | 9/32 |
| NasopharyngitisInfections and infestations | 9/32 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 8/32 |
| EczemaSkin and subcutaneous tissue disorders | 8/32 |
| GastroenteritisInfections and infestations | 7/32 |
| Immunisation reactionInjury, poisoning and procedural complications | 6/32 |
| Age, Continuous(months) | Nirsevimab 50 mg/100 mg |
|---|---|
| As-Treated Set 1 | 2.32 ± 2.39 |
| As-Treated Set 2 | 2.32 ± 2.43 |
| Sex: Female, Male(Participants) | Nirsevimab 50 mg/100 mg |
|---|---|
| As-Treated Set 1 — Female | 15 |
| As-Treated Set 1 — Male | 18 |
| As-Treated Set 2 — Female | 14 |
| As-Treated Set 2 — Male | 18 |
| Race/Ethnicity, Customized(Participants) | Nirsevimab 50 mg/100 mg |
|---|---|
| As-Treated Set 1 — Asian | 33 |
| As-Treated Set 2 — Asian | 32 |
| Ethnicity (NIH/OMB)(Participants) | Nirsevimab 50 mg/100 mg |
|---|---|
| As-Treated Set 1 — Hispanic or Latino | 0 |
| As-Treated Set 1 — Not Hispanic or Latino | 33 |
| As-Treated Set 1 — Unknown or Not Reported | 0 |
| As-Treated Set 2 — Hispanic or Latino | 0 |
| As-Treated Set 2 — Not Hispanic or Latino | 32 |
| As-Treated Set 2 — Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2023 to primary completion in Jul 2025, 23 months.
Results were first posted in Apr 2026, 8 months after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 23 months is above that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab
Respiratory Syncytial Virus Infections →